Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 7,810,000 | 7,999,902 | 6,772,800 | 6,740,100 | 6,805,600 |
| Cost of Goods | 2,072,100 | 2,050,200 | 1,430,800 | 1,953,200 | 1,878,600 |
| Gross Profit | 5,737,900 | 5,949,699 | 5,342,000 | 4,786,900 | 4,927,000 |
| Operating Expenses | 3,333,700 | 4,032,700 | 3,461,600 | 3,383,700 | 3,772,300 |
| Operating Income | 2,404,300 | 1,917,202 | 1,881,200 | 1,403,400 | 1,155,300 |
| Other Income | -350,700 | -77,302 | -635,900 | 190,500 | 321,100 |
| Pre-tax Income | 2,053,600 | 1,839,900 | 1,245,300 | 1,593,900 | 1,476,400 |
| Income Tax | 150,700 | 113,800 | 135,200 | 203,700 | 121,100 |
| Net Income Continuous | 1,902,900 | 1,726,100 | 1,110,100 | 1,390,200 | 1,355,300 |
| Net Income | $1,902,900 | $1,726,100 | $1,110,100 | $1,390,200 | $1,355,300 |
| EPS Basic Total Ops | 2.11 | 1.91 | 1.22 | 1.53 | 1.49 |
| EPS Basic Continuous Ops | 2.11 | 1.91 | 1.22 | 1.53 | 1.49 |
| EPS Diluted Total Ops | 2.10 | 1.88 | 1.22 | 1.53 | 1.49 |
| EPS Diluted Continuous Ops | 2.10 | 1.89 | 1.22 | 1.53 | 1.49 |
| EBITDA(a) | $2,840,000 | $2,362,902 | $2,263,500 | $1,772,700 | $1,505,600 |